

RECURRENCE FREE INTERVAL 12 MONTHS FOLLOWING LOCAL TREATMENT OF CANINE MAST CELL TUMOURS WITH A SINGLE INTRATUMORAL INJECTION OF TIGILANOL TIGLATE (STELFONTA®)

OBJECTIVES

To evaluate the durability of the tigilanol tiglate (TT) treatment response achieved at day 28 in the US study by assessing mast cell tumour (MCT) recurrence at the treatment site 6 and 12 months after TT.

MATERIALS & METHODS


- **Animals:**
 - 85 of 116 (73%) dogs had achieved a complete response at day 28 following a single injection.
- **Evaluations:**
 - Tumour site assessments made at 6 and 12 months following treatment.
 - Dogs retrospectively assessed for presence or absence of MCT at the treated site in patients available for assessment.

RESULTS

- At 12 months following a single TT treatment, 64 patients were evaluable with 21 patients unavailable to assess.
- 57 (89%) of patients remained tumour free at the treatment site.
- 7 (11%) of patients had developed recurrence at the treatment site.
- All recurrences occurred within the first 6 months, predominantly (71%) in the first 12 weeks following TT treatment.

CLINICAL INTEREST

A single intratumoral dose of tigilanol tiglate achieved good efficacy at day 28 with durability for 12 months.



REFERENCES

Jones PD, Campbell JE, Brown G, Johannes CM, Reddell P. Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. J Vet Intern Med. 2021 Jan-Feb; 35(1): 451–455